
Delilah Alvarado
Associate EditorDelilah is an associate editor for BioPharma Dive. Before Industry Dive she covered business tech and startup news and has reported on social issues, politics and culture. She has a B.S. from Texas State University and is obsessed with dogs and horror films.
89 articles by Delilah Alvarado
-
Moderna reports positive RSV vaccine results, pressuring Pfizer, GSK
Jan. 18, 2023 -
Leap Therapeutics to buy Flame Biosciences in all-stock deal
Jan. 17, 2023 -
EMA weighs new safety guidance for Novartis’ gene therapy Zolgensma
Jan. 13, 2023 -
JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor
Jan. 11, 2023 -
Novavax’s Erck to depart after 12 years as CEO
Jan. 9, 2023 -
5 FDA decisions to watch in the first quarter
Jan. 9, 2023 -
Ensoma buys a startup to advance ‘in vivo’ cell therapy work
Jan. 6, 2023 -
Kenvue, J&J’s consumer health unit, files for an IPO in step toward split
Jan. 5, 2023 -
Prevail, Capsida partner to develop gene therapies for nervous system diseases
Jan. 4, 2023 -
Pfizer says hemophilia B gene therapy controlled bleeding in key study
Dec. 29, 2022 -
Hearing loss biotech Otonomy plans to dissolve
Dec. 20, 2022 -
Ferring wins FDA approval for bladder cancer gene therapy
Dec. 19, 2022 -
Sio Gene Therapies to dissolve after years of setbacks
Dec. 15, 2022 -
Cytokinetics heart drug voted down by FDA panel
Dec. 14, 2022 -
Black Diamond spins out new biotech to develop cancer drugs
Dec. 13, 2022 -
Biotech layoffs claim more jobs at Sensei, Instil, TherapeuticsMD
Dec. 9, 2022 -
Immune drug developer Apogee emerges as first spinout of biotech Paragon
Dec. 7, 2022 -
Verve shares slide after company reveals details on FDA trial hold
Dec. 6, 2022 -
TherapeuticsMD to offload drugs to Australia’s Mayne after failed buyout
Dec. 5, 2022 -
J&J’s Duato to replace departing Gorsky as board chair
Dec. 2, 2022 -
Roche study failure gives Alzheimer’s researchers new clues in drug quest
Dec. 1, 2022 -
Sana reshuffles drug pipeline, becoming latest biotech to cut staff
Nov. 30, 2022 -
Spectrum to lay off R&D staff after FDA drug rejection
Nov. 28, 2022 -
Novartis, research group to advance new kind of malaria drug into late-stage test
Nov. 23, 2022 -
Biotech ObsEva sells drug rights to forestall funding crunch
Nov. 22, 2022